Oridonin attenuates atherosclerosis by inhibiting foam macrophage formation and inflammation through FABP4/PPARγ signalling
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oridonin attenuates atherosclerosis by inhibiting foam macrophage formation and inflammation through FABP4/PPARγ signalling
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-31
DOI
10.1111/jcmm.18000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PPAR-γ Activation Alleviates Osteoarthritis through Both the Nrf2/NLRP3 and PGC-1α/Δψm Pathways by Inhibiting Pyroptosis
- (2023) Zhencheng Feng et al. PPAR Research
- Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice
- (2023) Lei Wang et al. INFLAMMOPHARMACOLOGY
- Inflammasome activation and pyroptosis via a lipid-regulated SIRT1-p53-ASC axis in macrophages from male mice and humans
- (2022) Yimao Huang et al. ENDOCRINOLOGY
- Oridonin alleviates hyperbilirubinemia through activating LXRα-UGT1A1 axis
- (2022) Zhikun Zhan et al. PHARMACOLOGICAL RESEARCH
- Intestinal fatty acid binding protein: A rising therapeutic target in lipid metabolism
- (2022) Xi Huang et al. PROGRESS IN LIPID RESEARCH
- Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells
- (2021) Sabrina Robichaud et al. Autophagy
- Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
- (2021) Salim S. Virani et al. CIRCULATION
- Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 monoclonal antibodies
- (2021) Adel Hajj Ali et al. CURRENT MEDICINAL CHEMISTRY
- IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
- (2021) Paul M Ridker et al. LANCET
- The changing landscape of atherosclerosis
- (2021) Peter Libby NATURE
- Targeting inflammation in atherosclerosis — from experimental insights to the clinic
- (2021) Oliver Soehnlein et al. NATURE REVIEWS DRUG DISCOVERY
- Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB
- (2021) Yu Zhu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE−/− mice atherosclerosis
- (2021) Lingbo Xu et al. LABORATORY INVESTIGATION
- Network pharmacology: curing causal mechanisms instead of treating symptoms
- (2021) Cristian Nogales et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Smooth muscle 22 alpha protein inhibits VSMC foam cell formation by supporting normal LXRα signaling, ameliorating atherosclerosis
- (2021) Dan-Dan Zhang et al. Cell Death & Disease
- Oridonin suppresses autophagy and survival in rheumatoid arthritis fibroblast-like synoviocytes
- (2020) Shou-Di He et al. PHARMACEUTICAL BIOLOGY
- Magnolol alleviates Alzheimer's disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ
- (2020) Zhishen Xie et al. BIOMEDICINE & PHARMACOTHERAPY
- SnapShot: FABP Functions
- (2020) Bing Li et al. CELL
- Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
- (2020) Ron C Hoogeveen et al. CLINICAL CHEMISTRY
- Oridonin alleviates d‐ Gal N/LPS ‐induced acute liver injury by inhibiting NLRP3 inflammasome
- (2020) Tao Zhang et al. DRUG DEVELOPMENT RESEARCH
- An Overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions
- (2020) Desislava (Daisy) Ilchovska et al. AUTOIMMUNITY REVIEWS
- Salidroside simultaneously reduces de novo lipogenesis and cholesterol biosynthesis to attenuate atherosclerosis in mice
- (2020) Tongxin Song et al. BIOMEDICINE & PHARMACOTHERAPY
- Immunity and Inflammation in Atherosclerosis
- (2019) Dennis Wolf et al. CIRCULATION RESEARCH
- Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
- (2019) Magnus Bäck et al. Nature Reviews Cardiology
- Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases
- (2019) Masato Furuhashi Journal of Atherosclerosis and Thrombosis
- Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications
- (2019) Agha Zeeshan Mirza et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Atherosclerosis and Nanomedicine Potential: Current Advance and Future Opportunities
- (2019) Fan Jiang et al. CURRENT MEDICINAL CHEMISTRY
- Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways
- (2019) Huahong Yang et al. Cell Communication and Signaling
- Antioxidants and Atherosclerosis: Mechanistic Aspects
- (2019) Khojasteh Malekmohammad et al. Biomolecules
- Beneficial effects of Oridonin on myocardial ischemia/reperfusion injury: Insight gained by metabolomic approaches
- (2019) Junhong Zhang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A FABP4-PPARγ signaling axis regulates human monocyte responses to electrophilic fatty acid nitroalkenes
- (2019) M. Lamas Bervejillo et al. Redox Biology
- Combination of tanshinone IIA and astragaloside IV attenuate atherosclerotic plaque vulnerability in ApoE(-/-) mice by activating PI3K/AKT signaling and suppressing TRL4/NF-κB signaling
- (2019) Nanding Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment
- (2019) Sanne J. C. M. Frambach et al. PHARMACOLOGICAL REVIEWS
- Regulation of macrophage immunometabolism in atherosclerosis
- (2018) Graeme J. Koelwyn et al. NATURE IMMUNOLOGY
- Transcriptional regulation of macrophage cholesterol efflux and atherogenesis by a long noncoding RNA
- (2018) Tamer Sallam et al. NATURE MEDICINE
- Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities
- (2017) Weiyan Cheng et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- NF-κB inhibitors that prevent foam cell formation and atherosclerotic plaque accumulation
- (2017) Jesse D. Plotkin et al. Nanomedicine-Nanotechnology Biology and Medicine
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- FABP4/aP2 Regulates Macrophage Redox Signaling and Inflammasome Activation via Control of UCP2
- (2016) Kaylee A. Steen et al. MOLECULAR AND CELLULAR BIOLOGY
- Antitumor and Antibacterial Derivatives of Oridonin: A Main Composition of Dong-Ling-Cao
- (2016) Dahong Li et al. MOLECULES
- CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
- (2016) Yoko Kojima et al. NATURE
- Epidermal Fatty Acid Binding Protein Promotes Skin Inflammation Induced by High-Fat Diet
- (2015) Yuwen Zhang et al. IMMUNITY
- LXR-Mediated ABCA1 Expression and Function Are Modulated by High Glucose and PRMT2
- (2015) Maryem A. Hussein et al. PLoS One
- The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells
- (2012) Hiu-Yee Kwan et al. JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now